KIF16B

Across TCGA pan-cancer cohorts, KIF16B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KIF16B data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher KIF16B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated KIF16B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, BRCA, and LIHC are the cancer types where KIF16B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.933	0.432	.011	26	view →
BRCA	OS	Median	II,III,IV	0.182	0.568	<.001	22	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	15	view →
PRAD	OS	Median	All	0.939	0.995	.003	4	view →
SARC	DFS	Median	All	0.127	0.611	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KIF16B–UCEC (DFS)

Open the UCEC breakdown →